These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 24100872)

  • 21. A model for reduced HIV-1 viral load monitoring in resource-limited settings.
    Bryant L; Smith N; Keiser P
    J Int Assoc Provid AIDS Care; 2013; 12(1):67-71. PubMed ID: 22553318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries.
    Petrella M; Brenner B; Loemba H; Wainberg MA
    Drug Resist Updat; 2001 Dec; 4(6):339-46. PubMed ID: 12030782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings.
    Johannessen A; Trøseid M; Calmy A
    J Antimicrob Chemother; 2009 Dec; 64(6):1126-9. PubMed ID: 19776036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV and drug resistance - interpretation and therapeutic progress.
    Gürtler L
    Intervirology; 2012; 55(2):77-8. PubMed ID: 22286873
    [No Abstract]   [Full Text] [Related]  

  • 26. The measurement of HIV-1 viral load in resource-limited settings: how and where?
    Rouet F; Rouzioux C
    Clin Lab; 2007; 53(3-4):135-48. PubMed ID: 17447649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy.
    Lihana RW; Lwembe RM; Bi X; Ochieng W; Panikulam A; Palakudy T; Musoke R; Owens M; Ishizaki A; Okoth FA; Songok EM; Ichimura H
    J Clin Virol; 2011 Oct; 52(2):123-8. PubMed ID: 21798798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Need for newer antiretroviral drugs in India.
    Kumarasamy N; Ganguly M
    Indian J Med Res; 2009 Dec; 130(6):669-70. PubMed ID: 20090124
    [No Abstract]   [Full Text] [Related]  

  • 29. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
    J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?
    Socías ME; Rotryng F; Lapadula P; Medrano M; Paz D; Stern L; Lambierto A; Pryluka D
    J Infect Dev Ctries; 2013 Aug; 7(8):593-9. PubMed ID: 23949294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of HIV infection after triple class failure.
    Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A
    New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings.
    Stevens WS; Scott LE; Crowe SM
    J Infect Dis; 2010 Apr; 201 Suppl 1():S16-26. PubMed ID: 20225942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients.
    MacArthur RD
    AIDS Rev; 2009; 11(4):223-30. PubMed ID: 19940949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy: treatment-experienced individuals.
    Calvo KR; Daar ES
    Infect Dis Clin North Am; 2014 Sep; 28(3):439-56. PubMed ID: 25151565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.